NEWS OF MEDICINE REVIEWS
- Authors: - -
- Issue: Vol 28, No 11 (2021)
- Pages: 10-12
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/313271
- ID: 313271
Cite item
Open Access
Access granted
Abstract
Full Text
References
- Инструкция по медицинскому применению препарата Фесго®. ЛП-007317.
- Инструкция по медицинскому применению препарата Герцептин® П N01 5932/01.
- Инструкция по медицинскому применению препарата Перьета® РУ ЛП-002034.
- Tan A., et al. Subcutaneous administration of the fixed-dose combination of trastuzumab and pertuzumab in combination with chemotherapy in HER2-positive early breast cancer: primary analysis of the phase III, multicenter, randomized, open-label, two-arm FeDeriCa study. Presented at SABCS, 2019 Dec 10-14; San Antonio, Texas. Abstract #PD4-07.
- Клинические испытания. Исследование по оценке фармакокинетики, эффективности и безопасности подкожного введения фиксированных доз пертузумаба и трастузумаба в сочетании с химиотерапией у участников с HER2-положительным ранним раком молочной железы (FeDeriCa). URL: https://clinicaltrials.gov/ct2/show/NCT03493854 (доступ: июнь 2020 г.).
- O'Shaughnessy J., et al. Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study. Eur J Cancer. 2021;1 52:223-32.
- Halozyme. Технология доставки лекарств Enhanze®. URL: https://www.halozyme.com/enhanze/overview/default.aspx (доступ: июнь 2020 г.).
- Iqbal N., Iqbal N. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. Mol Biol Int. 2014;2014:852748.
- Baselga J., Swain S.M. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. 2009;9:463-75.
- Gianni L., et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25-32.
- Minckwitz G., et al. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. N Engl J Med. 2017;13;377(2):122-31.
- Swain S.M., et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;19;372(8):724-34.
- Wolff A.C., et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31): 3997-4013.
Supplementary files
